



BinaxNOW™ COVID-19 Ag Card will help you feel more confident about your child's COVID-19 status.

A rapid, reliable and easy-to-use test will help us have a bit more normalcy in our daily lives.



HERE'S HOW THE TEST WORKS

CONFIDENCE

Rapid antigen testing helps identify those who are contagious to help prevent the spread of the disease.

RESULTS

Negative results mean a person can resume their normal activities and should continue to stay vigilant, including following guidelines for hand washing, wearing masks and social distancing. If the test is positive, the person will be advised to quarantine and see their doctor. Schools using NAVICA may receive their test on the mobile app.



SAMPLE

A healthcare administrator takes a nasal swab from the student, faculty, or staff being tested.

INSERT

The nasal swab is then inserted into the test card.

TEST

In 15 minutes, a line will indicate whether the person has tested positive or negative for COVID-19 (one line indicates negative, two lines indicate positive).

WHAT IS ANTIGEN TESTING?

Antigen testing is designed to identify proteins of the SARS-CoV-2 virus. Rapid antigen tests are highly portable, easy to use, affordable and provide fast results. BinaxNOW is a rapid antigen test for detecting active infection in persons suspected of COVID-19 in the first seven days of symptoms.

WHAT IS NAVICA?

NAVICA is a complementary app that pairs with BinaxNOW. This first-of-its-kind app will allow people who test negative to have a temporary encrypted digital pass that displays their results, similar to an airline boarding pass. This allows organizations to verify negative test results—enabling people to move about with greater confidence.

To learn more about antigen testing and the science behind it, visit www.navica.abbott.

DISCLAIMER: The BinaxNOW™ COVID-19 Ag Card has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.